Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Resch, B; Gusenleitner, W; Nuijten, MJ; Lebmeier, M; Wittenberg, W.
Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria.
Clin Ther. 2008; 30(4): 749-760.
Doi: 10.1016/j.clinthera.2008.03.014
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Resch Bernhard
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- OBJECTIVE: The aim of this study was to estimate the cost-effectiveness of palivizumab, a monoclonal antibody against severe respiratory syncytial virus infection, in high-risk infants in Austria. METHODS: A decision tree model was developed to determine cost-effectiveness in infants born prematurely (
- Find related publications in this database (using NLM MeSH Indexing)
- Antibodies, Monoclonal - economics
- Antiviral Agents - economics
- Austria - epidemiology
- Child -
- Child, Preschool -
- Cost-Benefit Analysis -
- Drug Costs -
- Hospitalization - statistics and numerical data
- Humans -
- Incidence -
- Infant -
- Life Expectancy -
- Prognosis -
- Respiratory Syncytial Virus Infections - drug therapy
- Risk Factors -
- Survival Rate - trends
- Find related publications in this database (Keywords)
- respiratory syncytial virus
- palivizumab
- cost-effectiveness